Asia Pacific Plasma Fractionation Market By Product, By Sector, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

Asia Pacific Plasma Fractionation Market By Product, By Sector, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

  • April 2021 •
  • 68 pages •
  • Report ID: 6073566 •
  • Format: PDF
The Asia Pacific Plasma Fractionation Market would witness market growth of 11.7% CAGR during the forecast period (2021-2027).

Asia-Pacific displays attractive opportunities for leading players operating in the plasma fractionation market. This is due to the existence of governmental bodies that control and manage plasma collection, fractionation, and sales are the primary aspects that are fueling the growth of the plasma fractionation market. Moreover, increasing cases of medical conditions like high fever with thrombocytopenia syndrome (SFTS), hemophilia, and primary & secondary immune deficiencies also propel the development of the market.

Moreover, the surging geriatric population, increasing government support through Medicaid and healthcare policies, and improvements in the healthcare units are some of the determinants for the growth of the plasma fractional market. In addition, key makers are aiming to expand their geographical presence in developing countries of APAC to exploiter the untapped opportunities. This, in turn, would support the growth of the regional plasma fractionation market.

In addition, the plasma fractionation market would witness bright growth prospects due to a surge in the usage of immunoglobulins and alpha-1-antitrypsin in different domains of medicine across the globe. Moreover, untapped growth opportunities in developing countries would present various attractive possibilities for the growth of the global market during the forecast period. On the other hand, the growth of the would be hampered by the huge price of plasma-derived products.

The Immunoglobulins market dominated the Singapore Plasma Fractionation Market by Product in 2020, thereby, achieving a market value of $284.7 Million by 2027. The Albumin market is showcasing a CAGR of 11.8% during (2021 - 2027). Additionally, The Coagulation factor VIII market is expected to witness highest CAGR of 13.9% during (2021 - 2027).

Based on Product, the market is segmented into Immunoglobulins, Albumin, Coagulation factor VIII and Coagulation factor IX. Based on Sector, the market is segmented into Private Sector and Public Sector. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Emergent BioSolutions, Inc., CSL Limited, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, LFB S.A, Biotest AG (Tiancheng International Investment Limited), Sanquin Blood Supply Foundation, and Bio Products Laboratory Limited.

Scope of the Study

Market Segments covered in the Report:

By Product

• Immunoglobulins

• Albumin

• Coagulation factor VIII

• Coagulation factor IX

By Sector

• Private Sector

• Public Sector

By Country

• China

• Japan

• India

• South Korea

• Singapore

• Malaysia

• Rest of Asia Pacific

Companies Profiled

• Emergent BioSolutions, Inc.

• CSL Limited

• Grifols S.A.

• Octapharma AG

• Takeda Pharmaceutical Company Limited

• Kedrion S.p.A


• Biotest AG (Tiancheng International Investment Limited)

• Sanquin Blood Supply Foundation

• Bio Products Laboratory Limited

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.